Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
1 Major Factor Behind the Healthcare Sector's Recent Surge
10:55am, Tuesday, 09'th Dec 2025
Eli Lilly's GLP-1 drug became the world's best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones.
3 Top Dividend Stocks to Buy in December
04:44am, Tuesday, 09'th Dec 2025
AbbVie is a Dividend King that has proven its resilience. Ares Capital offers an ultra-high yield, with solid near-term and long-term growth prospects.
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
06:46pm, Monday, 08'th Dec 2025
AbbVie (ABBV) concluded the recent trading session at $223.12, signifying a -1.31% move from its prior day's close.
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development
01:30am, Monday, 08'th Dec 2025
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving
The Generational Shift I See Now - And My 33 Stocks For What's Coming
07:30am, Sunday, 07'th Dec 2025
I see a generational opportunity in quality stocks, defined by high ROE, stable earnings growth, and low debt. Quality stocks have underperformed AI-driven leaders, creating rare relative value and at
Cerity Partners LLC Has $210.15 Million Holdings in AbbVie Inc. $ABBV
04:09am, Sunday, 07'th Dec 2025
Cerity Partners LLC increased its position in AbbVie Inc. (NYSE: ABBV) by 15.6% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The
The Pharmaceutical Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar.
08:45am, Saturday, 06'th Dec 2025
AbbVie's third-quarter results exceeded Wall Street's expectations. Sales from the pharmaceutical company's three top drugs are soaring.
Could Buying AbbVie Today Set You Up for Life?
09:15am, Thursday, 04'th Dec 2025
AbbVie has performed exceedingly well over the past 12 years. The company still has many of the traits that led to that result.
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
08:40am, Thursday, 04'th Dec 2025
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
Groupe la Francaise Purchases 6,466 Shares of AbbVie Inc. $ABBV
06:16am, Thursday, 04'th Dec 2025
Groupe la Francaise lifted its position in shares of AbbVie Inc. (NYSE: ABBV) by 34.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
04:53pm, Wednesday, 03'rd Dec 2025
AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 03'rd Dec 2025
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie Inc. (NYSE:ABBV) Receives Average Rating of “Moderate Buy” from Analysts
02:16am, Wednesday, 03'rd Dec 2025
AbbVie Inc. (NYSE: ABBV - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-five research firms that are covering the stock, MarketBeat reports. Ten investment an
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
08:15am, Tuesday, 02'nd Dec 2025
Data being presented showcases AbbVie's breadth and depth of research across a range of therapeutic modalities such as T-Cell Engagers, BCL-2 Inhibitors and Antibody-Drug Conjugates for a spectrum of
À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine
03:23am, Tuesday, 02'nd Dec 2025
/PRNewswire/ -- AbbVie (NYSE: ABBV) a annoncé aujourd'hui les premiers résultats de l'étude pivot de phase 3 ECLIPSE, qui évalue l'innocuité, l'efficacité et
